Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel enzyme inhibitors from microbial source claimed by HMR as antidiabetics

Dec. 29, 1998

Amgen's rights to NESP affirmed by arbitrator panel

Dec. 28, 1998

Y5 antisense ODN used to confirm involvement of this receptor in the regulation of feeding

Dec. 23, 1998

Another novel class of nonsteroidal progesterone receptor agonists designed by Ligand

Dec. 23, 1998

Somatostatin agonists from Takeda claimed for diabetes and its complications

Dec. 23, 1998

Structure revealed by Tanabe Seiyaku for potent, orally active SGLT inhibitor

Dec. 22, 1998

AxyS and Merck extend osteoporosis collaboration

Dec. 22, 1998

Kinetek initiates phase I studies of type II diabetes treatment

Dec. 22, 1998

Preliminary analysis of phase II trial indicates efficacy and safety of Topiglan gel

Dec. 21, 1998

E.U.-wide Muse approval triggers license and milestone payments from Astra

Dec. 21, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...